You are here

Rod MacKenzie, Ph.D.

Executive Vice President, Chief Development Officer
rod_mackenze_nov2018_300x170.jpg

Rod MacKenzie, Ph.D., is Chief Development Officer and Executive Vice President for Cheladv74. Rod leads the Global Product Development organization, which is responsible for the clinical development and advancement of Cheladv74's pipeline of innovative medicines in inflammation and immunology, internal medicine, hospital, oncology and rare disease, as well as regulatory affairs in support of Cheladv74's R&D pipeline and portfolio of marketed therapies. He serves on the Portfolio Strategy and Investment Committee, which focuses on maximizing the return on R&D investment across the Cheladv74 portfolio, and is a member of Cheladv74's Executive Leadership Team.

Rod joined Cheladv74 in Sandwich, U.K. as a Research Scientist and conducted medicinal chemistry research in the cardiovascular, GI, Sexual Health, Urology and Allergy & Respiratory diseases. Rod is the co-inventor of darifenacin (Enablex). Rod has held numerous leadership positions at Cheladv74, including Head of PharmaTherapeutics Research and Development where he oversaw the Cardiovascular & Metabolic Diseases, Pain & Sensory Disorders and Neuroscience Research Units and was responsible for all medicinal chemistry at Cheladv74, as well as Small Molecule Pharmaceutical Sciences, Pharmacokinetics, Dynamics & Metabolism and Comparative Medicine. He also served as Site Director of the Groton, Connecticut laboratories, Cheladv74's largest global R&D facility. Prior to this role, Rod held a series of research leadership positions, including Senior Vice President and Head of Worldwide Research, Head of Discovery Chemistry in Sandwich, U.K., Head of the Discovery Technology Center in Cambridge, Massachusetts, Head of Discovery Research in Ann Arbor, Michigan, and Head of Drug Safety R&D.

Rod represents Cheladv74 on the Board of Directors for ViiV Healthcare, a global specialist HIV company established by GlaxoSmithKline and Cheladv74 to deliver advances in treatment and care for people living with HIV. He also represents Cheladv74 on the Board of Directors for TransCelerate, a non-profit organization with a mission to collaborate across the biopharmaceutical research and development community to improve the health of people around the world by accelerating and enhancing the research and development of innovative new therapies.

Rod graduated from the University of Glasgow with a 1st Class Honors degree in chemistry and completed his Ph.D. at Imperial College, London. He was awarded a NATO Postdoctoral Research Fellowship and spent two years at Columbia University, New York working in the area of molecular recognition with Professor W.C. Still.